Human epidermal growth factor receptor 2 testing in breast cancer | Zendy

Tatjana Ivković-Kapicl | Zendy; Slavica KneževićUšaj | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Human epidermal growth factor receptor 2 testing in breast cancer

Author(s) -

Tatjana Ivković-Kapicl,

Slavica KneževićUšaj

Publication year - 2010

Publication title -

medicinski pregled

Language(s) - English

Resource type - Journals

eISSN - 1820-7383

pISSN - 0025-8105

DOI - 10.2298/mpns1002069i

Subject(s) - medicine , human epidermal growth factor receptor 2 , breast cancer , cancer , oncology , epidermal growth factor receptor , epidermal growth factor , cancer research , receptor

Testing for human epidermal growth factor receptor-2 in breast cancer at the time of primary diagnosis is now the standard of care. Positivity for epidermal growth factor receptor-2 in breast cancer is a prognostic factor regarding tumor aggressiveness and a predictive factor for response to Herceptin. Accurate assessment is essential to ensure that all patients who may benefit from Herceptin are correctly identified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research